[go: up one dir, main page]

MX2017004526A - Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. - Google Patents

Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.

Info

Publication number
MX2017004526A
MX2017004526A MX2017004526A MX2017004526A MX2017004526A MX 2017004526 A MX2017004526 A MX 2017004526A MX 2017004526 A MX2017004526 A MX 2017004526A MX 2017004526 A MX2017004526 A MX 2017004526A MX 2017004526 A MX2017004526 A MX 2017004526A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
fap
combination therapy
antibodies specific
chemotherapeutic agents
Prior art date
Application number
MX2017004526A
Other languages
English (en)
Inventor
Majety Meher
Wartha Katharina
Krieter Oliver
Friess Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017004526A publication Critical patent/MX2017004526A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a anticuerpos biespecíficos que comprenden al menos un sitio de unión a antígeno específico para DR5 y al menos un sitio de unión a antígeno específico para FAP, a anticuerpos específicos para DR5, y en particular a terapias combinadas que emplean dichos anticuerpos biespecíficos y un agente quimioterapéutico, y al uso de estas terapias combinadas para el tratamiento del cáncer.
MX2017004526A 2014-10-08 2015-10-06 Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. MX2017004526A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14188176 2014-10-08
EP15151221 2015-01-15
EP15160231 2015-03-23
EP15179117 2015-07-30
PCT/EP2015/072974 WO2016055432A2 (en) 2014-10-08 2015-10-06 Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MX2017004526A true MX2017004526A (es) 2017-06-07

Family

ID=54249506

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004526A MX2017004526A (es) 2014-10-08 2015-10-06 Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.

Country Status (14)

Country Link
US (1) US20180064808A1 (es)
EP (1) EP3204412B1 (es)
JP (2) JP6810687B2 (es)
KR (1) KR20170063946A (es)
CN (1) CN106999580B (es)
AU (1) AU2015330087A1 (es)
BR (1) BR112017006468A2 (es)
CA (1) CA2962124A1 (es)
IL (1) IL251203A0 (es)
MX (1) MX2017004526A (es)
RU (1) RU2017116020A (es)
SG (1) SG11201702805TA (es)
WO (1) WO2016055432A2 (es)
ZA (1) ZA201702050B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
KR101780131B1 (ko) 2010-08-13 2017-09-19 로슈 글리카트 아게 항-fap 항체 및 이의 사용 방법
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
ES2806500T3 (es) 2015-01-20 2021-02-17 Igm Biosciences Inc Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas
EP3356403A2 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
CN109983121A (zh) 2016-06-30 2019-07-05 昂克诺斯公司 治疗性多肽的假型化溶瘤病毒递送
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
PE20191360A1 (es) 2017-03-10 2019-10-01 Hoffmann La Roche Metodo para producir anticuerpos multiespecificos
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MX2021003548A (es) 2018-10-01 2021-05-27 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
KR20210134321A (ko) * 2019-02-01 2021-11-09 노바록 바이오테라퓨틱스 리미티드 항-클라우딘 18 항체 및 이의 이용 방법
WO2021151005A1 (en) * 2020-01-22 2021-07-29 Ansun Biopharma, Inc. Inhaled das181 to treat cancer in the lung
AR121706A1 (es) * 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
HRP20141032T1 (hr) * 2009-09-29 2015-01-30 Roche Glycart Ag Bispecifiäśna agonistiäśka protutijela receptora smrtnosti
HUE029257T2 (en) * 2009-12-29 2017-02-28 Aptevo Res And Dev Llc Heterodimer binding proteins and their use
KR101780131B1 (ko) * 2010-08-13 2017-09-19 로슈 글리카트 아게 항-fap 항체 및 이의 사용 방법
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2994487B1 (en) * 2013-05-07 2019-10-09 F.Hoffmann-La Roche Ag Trimeric antigen binding molecules

Also Published As

Publication number Publication date
WO2016055432A2 (en) 2016-04-14
ZA201702050B (en) 2018-05-30
CA2962124A1 (en) 2016-04-14
WO2016055432A3 (en) 2016-06-02
CN106999580B (zh) 2021-07-06
SG11201702805TA (en) 2017-05-30
BR112017006468A2 (pt) 2017-12-19
KR20170063946A (ko) 2017-06-08
RU2017116020A3 (es) 2019-04-05
EP3204412A2 (en) 2017-08-16
IL251203A0 (en) 2017-05-29
JP2021008476A (ja) 2021-01-28
AU2015330087A1 (en) 2017-04-06
RU2017116020A (ru) 2018-11-12
US20180064808A1 (en) 2018-03-08
JP6810687B2 (ja) 2021-01-06
CN106999580A (zh) 2017-08-01
JP2018502822A (ja) 2018-02-01
EP3204412B1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
IL302093B1 (en) Combination therapy involving anti-claudin 18.2 antibodies for cancer treatment
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
ZA201708265B (en) Tigit-binding agents and uses thereof
MX2020012573A (es) Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
NZ732568A (en) Antibodies targeting b-cell maturation antigen and methods of use
IL240060A0 (en) Treatment involving antibodies against claudin 2. 18 for the treatment of cancer
MX375221B (es) Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
GEAP202114756A (en) Combination therapy for the treatment of cancer
LT4339615T (lt) Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
MX2017015311A (es) Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
MX2017007097A (es) Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
SI2976360T1 (sl) Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
NZ725519A (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
NZ626513A (en) Anti-cd98 antibodies and methods of use thereof